Collaborators sought to develop/validate a human stem cell model for cardiotoxicity screening
A Manchester University researcher is seeking industrial or academic partners to help develop/validate their human pluripotent stem cell-cardiomyocyte (hPS-CM) model (derived from embryonic and induced stem cells) for screening cardiotoxicity in new drugs. The researcher is looking to collaborate with pharmaceutical industry partners to validate the model of hPS-CM as a standard model of screening for cardiotoxicity. To do this they would like access to a compound library with known cardiac toxicity to validate their system. They will screen the compounds for cardiotoxicity in their optimised hPS-CM assays.
The advice and guidance provided by an industry partner on using the assay in an industrial setting will be crucial to the successful application of this model. This partnering opportunity is part of CRACK IT Solutions (www.crackit.org.uk/share), offering academics and small companies the opportunity to showcase their ideas, technologies and products to the wider scientific community to find new partners to adopt, validate or further develop their research.